Enhanced Vergence Recovery Convalescence System with Real-time Feedback and AI-driven Analytics

Publication ID: 24-11857258_0001_PTD
Published: November 07, 2025
Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced Vergence Recovery Convalescence System with Real-time Feedback and AI-driven Analytics,” Published Technical Disclosure No. 24-11857258_0001_PTD, Published November 07, 2025, available at https://archive.pr1or.art/24-11857258_0001_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,258.

Summary of the Inventive Concept

An advanced dynamic vergence testing platform incorporating real-time feedback mechanisms, AI-powered predictive analytics, and remote monitoring capabilities to improve the accuracy and efficiency of vergence dysfunction diagnosis and treatment.

Background and Problem Solved

The original patent, 'Vergence recovery convalescence using dynamic vergence testing platform including 3D head mounted display system with integrated eye tracking technology,' had limitations in terms of providing real-time feedback, personalizing stimulus presentation, and optimizing treatment outcomes. The new inventive concept addresses these limitations by introducing a real-time feedback mechanism, AI-driven predictive analytics, and remote monitoring capabilities to enhance the accuracy and efficiency of vergence dysfunction diagnosis and treatment.

Detailed Description of the Inventive Concept

The enhanced vergence recovery convalescence system consists of a dynamic vergence testing platform with integrated eye tracking technology, a real-time feedback mechanism to adjust stimulus intensity based on a subject's physiological response, and an AI-powered predictive analytics module to forecast treatment outcomes and optimize treatment protocols. The system also includes a remote monitoring capability, enabling real-time data transmission for remote analysis. The platform is adapted for personalized stimulus presentation sequences based on a subject's vergence dysfunction diagnosis, ensuring more accurate and effective treatment. Additionally, the system incorporates machine learning algorithms to identify patterns in eye movement data, further improving the accuracy of vergence dysfunction diagnosis.

Novelty and Inventive Step

The new claims introduce the novel concept of real-time feedback mechanisms, AI-driven predictive analytics, and remote monitoring capabilities, which are not present in the original patent. The inventive step lies in the integration of these features to create a more accurate, efficient, and personalized vergence dysfunction diagnosis and treatment system.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept may include the use of augmented reality or virtual reality displays, the integration of additional sensors to track other physiological responses, or the development of mobile applications for remote monitoring and analysis. Variations of the system may also include different AI algorithms or machine learning models to improve the accuracy of predictive analytics and diagnosis.

Potential Commercial Applications and Market

The enhanced vergence recovery convalescence system has significant commercial potential in the healthcare industry, particularly in the fields of ophthalmology, optometry, and neurology. The system's ability to provide accurate and personalized diagnosis and treatment of vergence dysfunction can improve patient outcomes, reduce healthcare costs, and enhance the overall quality of life for individuals with vergence-related disorders.

CPC Classifications

SectionClassGroup
A A61 A61B3/113
A A61 A61B3/0041
G G02 G02B27/0093
G G02 G02B27/017

Original Patent Information

Patent NumberUS 11,857,258
TitleVergence recovery convalescence using dynamic vergence testing platform including 3D head mounted display system with integrated eye tracking technology
Assignee(s)NEUROLIGN USA, LLC